Beijing Fanzhi Medical Technology
Developer of nucleic acid diagnostic instruments, chips and other testing platforms
About Beijing Fanzhi Medical Technology
Beijing Fanzhi Medical Technology Co., Ltd., also known as FireGen Biomedicals, is a global biopharmaceutical company established on June 3, 2016. The company was founded by a team of returning scientists, Chinese Academy of Sciences (CAS) scientists, and clinical experts, including Dr. Song Keqing, who serves as the founder and CEO. His background in precision medicine has guided the firm's focus. Fanzhi Medical has secured significant funding, including a Series D round of over 100 million CNY in September 2023 and a Series D+ round of a similar scale.
The company specializes in developing and providing integrated solutions for disease diagnostics. Its business model revolves around providing comprehensive "sample-in, result-out" solutions, including detection instruments, chips, diagnostic reagents, and internet-based remote diagnosis and treatment products. It has developed core competencies across four key technology areas: nucleic acids, chips, machinery, and software. Product lines include nucleic acid extraction kits, PCR amplification reagents, and diagnostic tools for conditions like respiratory infections and cardiovascular diseases. The firm's offerings are designed to make advanced, rapid diagnostics accessible to a wide range of clients, from primary care institutions and hospitals to communities and households.
Headquartered in Beijing, Fanzhi Medical operates large-scale GMP facilities, R&D centers, and medical laboratories in several Chinese provinces and has a presence in the United States. The company serves a global client base across more than 30 countries, which includes hospitals, pharmaceutical companies, research institutions, and genetic testing companies. It holds over 150 authorized patents and has received regulatory approvals from China's NMPA, the US FDA, and the European Union's CE for dozens of its products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 9
- Open positions
- 1
- Dealroom signal
- 25.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Infections and Infectious Diseases, Genetics and genomics, Precision Medicine, Health Diagnostics, Diagnosis and Monitoring, medical testing, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 3 companies, latest Oct 2023
- Capital deployed
- $2.8M
- Preferred round
- SEED
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Aug 2025 | $14M | $55M | Herui Venture Capital | ↗ |
| SERIES D✓Equity / VC | Sep 2023 | $14M | $55M | Jianchuang Medical Growth Fund · GSR Capital · Zhilai Capital | ↗ |
Growth signals
Latest recorded traffic for Beijing Fanzhi Medical Technology is 650 monthly website visits, up 109.7% over the last three months. Beijing Fanzhi Medical Technology's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
BiofidelityRapid genomic biomarker detection for precision oncology |
Cambridge, United Kingdom | Operational | 29 | $61M | $96M |
Diatech PharmacogeneticsProvider of molecular diagnostic tools for precision medicine. |
Jesi, Italy | Operational | |||
CASBIOCRISPR-Cas gene therapies and point-of-care diagnostics |
Australia | Operational | |||
PierianDxEnables clinical labs to deliver patient-specific diagnosis and treatments |
St. Louis, United States | Acquired | |||
InflammatixDeveloping novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system |
Sunnyvale, United States | Operational | |||
GeneticurePharmacogenomic tests to control large, chronic diseases faster than trial/error |
Minneapolis, United States | Operational | |||
Visby MedicalInstrument-free, single-use, palm-sized PCR diagnostic devices. |
San Jose, United States | Operational | |||
| China | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hebei Xiancheng BiotechnologyChinaFine chemicals and pharmaceutical intermediates for industry
→
QM
Qiuhang (Zhejiang) Health ManagementHangzhou, China
→
QT
Qingdao Zhongjing Puhui Medical TechnologyChina
$11Mvaluation
Beijing Fanzhi Medical Technology in its local ecosystem
The Beijing Fanzhi Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
CAS Investment Management- JFJianchuang Medical Growth Fund
- GCGSR Capital
- ZCZhilai Capital
- HCHerui Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Fanzhi Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Fanzhi Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









